We therefore conclude that the decrease in CD16 expression on γδ T cells mediated by stimulation with zoledronate and IL-2 is not a disadvantage but can be even associated with increased anti-lymphoma activity of stimulated γδ T cells. This evidence concerns the gene IL2 and lymphoma.